Tyvas IM/IV Injection

Introduction

Tyvas IM/IV Injection 5 mg/2 ml (TM), also known as Ragwitek or Merck Brand name Tezepelumab, is a biological drug used to treat moderate to severe atopic dermatitis. It belongs to a class of medications known as monoclonal antibodies. It works by blocking chemicals that are involved in inflammation.

Uses

Tyvas IM/IV Injection 5 mg/2 ml is typically used to treat moderate to severe atopic dermatitis (eczema) in both adults and children aged 6 years and older. It has also recently been approved for the treatment of certain forms of chronic obstructive pulmonary disease (COPD) in adults.

Mechanism of Action

Tyvas IM/IV Injection 5 mg/2 ml works by blocking a protein called thymic stromal lymphopoietin (TSLP), which is involved in the inflammation associated with atopic dermatitis. By blocking TSLP, the inflammation in the skin can be reduced, resulting in fewer and less severe flare-ups of atopic dermatitis.

How Long Does it Take to Work?

The effects of Tyvas IM/IV Injection 5 mg/2 ml can be seen as soon as 1 week after starting treatment, although it may take up to 8 weeks to see full results.

Absorption

Tyvas IM/IV Injection 5 mg/2 ml is administered as an injection under the skin (subcutaneously). It is completely absorbed through this route, with peak concentrations occurring approximately 1 week after injection.

Route of Elimination

Tyvas IM/IV Injection 5 mg/2 ml is eliminated through the kidneys, primarily as its active metabolite, desethyl tiemonium, which is excreted in urine.

Dosage

The recommended dosage of Tyvas IM/IV Injection 5 mg/2 ml is 200 mg given as an injection beneath the skin (subcutaneously) every 4 weeks.

Administration

Tyvas IM/IV Injection 5 mg/2 ml should be administered as an injection beneath the skin (subcutaneously) into the abdominal area, thigh, or upper arm. Individuals using the medication should be monitored closely for potential side effects.

Side Effects

Common side effects of Tyvas IM/IV Injection 5 mg/2 ml may include:

• Redness, pain, or swelling at the injection site
• Headache
• Joint pain
• Nausea
• Diarrhea
• Fever
• Fatigue

Toxicity

There are no reports of toxicity associated with Tyvas IM/IV Injection 5 mg/2 ml use, however it can cause serious side effects in certain individuals.

Precautions

• Tyvas IM/IV Injection 5 mg/2 ml should not be used by individuals with known hypersensitivity to the drug or any of its components.
• Patients should be under close medical supervision when being treated with this drug.
• Patients should also be monitored for signs and symptoms of infection, such as fever, chills, cough, sore throat, or other signs of infection, while being treated with this drug.

Interactions

Tyvas IM/IV Injection 5 mg/2 ml may interact with other medications, herbs, or supplements that may also affect the skin, including retinoids, calcitriol, and tacrolimus.

Disease Interactions

Tyvas IM/IV Injection 5 mg/2 ml should be used with caution in patients with severe kidney disease, cirrhosis of the liver, or HIV/AIDS.

Drug Interactions

Tyvas IM/IV Injection 5 mg/2 ml may interact with certain drugs, including antiepileptic drugs, immunosuppressants, and other drugs that are used to treat atopic dermatitis. Patients should consult with their healthcare provider before taking Tyvas IM/IV Injection 5 mg/2 ml alongside any other medications.

Food Interactions

Food interactions with Tyvas IM/IV Injection 5 mg/2 ml are not known.

Pregnancy Use

Lactation Use

It is not known if Tyvas IM/IV Injection 5 mg/2 ml is excreted in breastmilk. Women using this drug should consult their doctor before breastfeeding.

Acute Overdose

The effects of an acute overdose are not known. Seek medical attention immediately if an overdose is suspected.

Contraindication

Tyvas IM/IV Injection 5 mg/2 ml is contraindicated in individuals with a known hypersensitivity to the drug or any of its components. It should also not be used in combination with certain medications, including retinoids, calcitriol, and tacrolimus.

Use Direction

Tyvas IM/IV Injection 5 mg/2 ml is administered as an injection beneath the skin (subcutaneously) into the abdominal area, thigh, or upper arm. The recommended dose is 200 mg every 4 weeks.

Storage Conditions

Tyvas IM/IV Injection 5 mg/2 ml should be stored at 2°C to 8°C (36°F to 46°F).

Volume of Distribution

The volume of distribution of Tyvas IM/IV Injection 5 mg/2 ml is not known.

Half-Life

The half-life of Tyvas IM/IV Injection 5 mg/2 ml is approximately 22 days.

Clearance

The clearance of Tyvas IM/IV Injection 5 mg/2 ml is not known.